LSN2424100: A novel, potent orexin-2 receptor antagonist with selectivity over orexin-1 receptors and activity in an animal model predictive of antidepressant-like efficacy

Frontiers in Neuroscience

Volumn , Issue 8 JAN, 2014, Pages

  Fitch, Thomas E ^a   Benvenga, Mark J ^a   Jesudason, Cynthia D ^a   Zink, Charity ^a   Vandergriff, Amy B ^a   Menezes, Michelle M ^a   Schober, Douglas A ^a   Rorick Kehn, Linda M ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Antidepressant; DRL; Hypocretin; Mouse; Neuropeptide; Orexin; OX2 antagonist; Rat

Indexed keywords

ANTIDEPRESSANT AGENT; BENZENESULFONAMIDE DERIVATIVE; CALCIUM; IMIPRAMINE; LSN 2424100; N [(1H IMIDAZOL 2 YL)METHYL] N [(1,1' BIPHENYL) 2 YL] 4 FLUOROBENZENESULFONAMIDE; OREXIN 1 RECEPTOR; OREXIN 2 RECEPTOR; OREXIN A; PROTEIN C FOS; RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ADULT; ANIMAL EXPERIMENT; ANTIDEPRESSANT ACTIVITY; ARTICLE; BINDING AFFINITY; CALCIUM CELL LEVEL; CALCIUM TRANSPORT; CELL STRAIN HEK293; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSAGE FORM COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PREFRONTAL CORTEX; PROTEIN EXPRESSION; RAT;

EID: 84898034348     PISSN: 16624548     EISSN: 1662453X     Source Type: Journal    
DOI: 10.3389/fnins.2014.00005     Document Type: Article

References (47)

1. Allard, J. S., Tizabi, Y., Shaffery, J. P., Trouth, C. O., and Manaye, K. (2004). Stereological analysis of the hypothalamic hypocretin/orexin neurons in an animal model of depression. Neuropeptides 38, 311-315. doi: 10.1016/j.npep.2004.06.004.
2. Aston-Jones, G., Smith, R. J., Moorman, D. E., and Richardson, K. A. (2009). Role of lateral hypothalamic orexin neurons in reward processing and addiction. Neuropharmacology 56(Suppl. 1), 112-121. doi: 10.1016/j.neuropharm.2008.06.060.
3. Borgland, S. L., Storm, E., and Bonci, A. (2008). Orexin B/hypocretin 2 increases glutamatergic transmission to ventral tegmental area neurons. Eur. J. Neurosci. 28, 1545-1556. doi: 10.1111/j.1460-9568.2008.06397.x.
4. Boutrel, B., Cannella, N., and De Lecea, L. (2010). The role of hypocretin in driving arousal and goal-oriented behaviors. Brain Res. 1314, 103-111. doi: 10.1016/j.brainres.2009.11.054.
5. Boutrel, B., Kenny, P. J., Specio, S. E., Martin-Fardon, R., Markou, A., Koob, G. F., et al. (2005). Role for hypocretin in mediating stress-induced reinstatement of cocaine-seeking behavior. Proc. Natl. Acad. Sci. U.S.A. 102, 19168-19173. doi: 10.1073/pnas.0507480102.
6. Brisbare-Roch, C., Dingemanse, J., Koberstein, R., Hoever, P., Aissaoui, H., Flores, S., et al. (2007). Promotion of sleep by targeting the orexin system in rats, dogs and humans. Nat. Med. 13, 150-155. doi: 10.1038/nm1544.
7. Brundin, L., Bjorkqvist, M., Petersen, A., and Traskman-Bendz, L. (2007). Reduced orexin levels in the cerebrospinal fluid of suicidal patients with major depressive disorder. Eur. Neuropsychopharmacol. 17, 573-579. doi: 10.1016/j.euroneuro.2007.01.005.
8. Chemelli, R. M., Willie, J. T., Sinton, C. M., Elmquist, J. K., Scammell, T., Lee, C., et al. (1999). Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell 98, 437-451. doi: 10.1016/S0092-8674(00)81973-X.
9. Del Cid-Pellitero, E., and Garzon, M. (2011). Hypocretin1/OrexinA-containing axons innervate locus coeruleus neurons that project to the Rat medial prefrontal cortex. Implication in the sleep-wakefulness cycle and cortical activation. Synapse 65, 843-857. doi: 10.1002/syn.20912.
10. De Lecea, L., Kilduff, T. S., Peyron, C., Gao, X., Foye, P. E., Danielson, P. E., et al. (1998). The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc. Natl. Acad. Sci. U.S.A. 95, 322-327. doi: 10.1073/pnas.95.1.322.
11. De Pablo, J. M., Parra, A., Segovia, S., and Guillamon, A. (1989). Learned immobility explains the behavior of rats in the forced swimming test. Physiol. Behav. 46, 229-237. doi: 10.1016/0031-9384(89)90261-8.
12. Drevets, W. C., Price, J. L., and Furey, M. L. (2008). Brain structural and functional abnormalities in mood disorders: implications for neurocircuitry models of depression. Brain Struct. Funct. 213, 93-118. doi: 10.1007/s00429-008-0189-x.
13. Furlong, T. M., Vianna, D. M., Liu, L., and Carrive, P. (2009). Hypocretin/orexin contributes to the expression of some but not all forms of stress and arousal. Eur. J. Neurosci. 30, 1603-1614. doi: 10.1111/j.1460-9568.2009.06952.x.
14. Gotter, A. L., Webber, A. L., Coleman, P. J., Renger, J. J., and Winrow, C. J. (2012). International union of basic and clinical pharmacology. LXXXVI. orexin receptor function, nomenclature and pharmacology. Pharmacol. Rev. 64, 389-420. doi: 10.1124/pr.111.005546.
15. Hirose, M., Egashira, S., Goto, Y., Hashihayata, T., Ohtake, N., Iwaasa, H., et al. (2003). N-acyl 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline: the first orexin-2 receptor selective non-peptidic antagonist. Bioorg. Med. Chem. Lett. 13, 4497-4499. doi: 10.1016/j.bmcl.2003.08.038.
16. Ito, N., Yabe, T., Gamo, Y., Nagai, T., Oikawa, T., Yamada, H., et al. (2008). I.c.v. administration of orexin-A induces an antidepressive-like effect through hippocampal cell proliferation. Neuroscience 157, 720-732. doi: 10.1016/j.neuroscience.2008.09.042.
17. Leonard, C. S., and Kukkonen, J. P. (2014). Orexin/hypocretin receptor signalling: a functional perspective. Br. J. Pharmacol. 171, 294-313. doi: 10.1111/bph.12296.
18. Lopez-Rubalcava, C., and Lucki, I. (2000). Strain differences in the behavioral effects of antidepressant drugs in the rat forced swimming test. Neuropsychopharmacology 22, 191-199. doi: 10.1016/S0893-133X(99)00100-1.
19. Lutter, M., Krishnan, V., Russo, S. J., Jung, S., Mcclung, C. A., and Nestler, E. J. (2008). Orexin signaling mediates the antidepressant-like effect of calorie restriction. J. Neurosci. 28, 3071-3075. doi: 10.1523/JNEUROSCI.5584-07.2008.
20. Malherbe, P., Borroni, E., Gobbi, L., Knust, H., Nettekoven, M., Pinard, E., et al. (2009). Biochemical and behavioural characterization of EMPA, a novel high-affinity, selective antagonist for the OX(2) receptor. Br. J. Pharmacol. 156, 1326-1341. doi: 10.1111/j.1476-5381.2009.00127.x.
21. Mayers, A. G., and Baldwin, D. S. (2005). Antidepressants and their effect on sleep. Hum. Psychopharmacol. 20, 533-559. doi: 10.1002/hup.726.
22. Mazure, C. M. (1998). Life stressors as risk factors in depression. Clin. Psychol. Sci. Pract. 5, 291-313. doi: 10.1111/j.1468-2850.1998.tb00151.x.
23. McAtee, L. C., Sutton, S. W., Rudolph, D. A., Li, X., Aluisio, L. E., Phong, V. K., et al. (2004). Novel substituted 4-phenyl-[1,3]dioxanes: potent and selective orexin receptor 2 (OX(2)R) antagonists. Bioorg. Med. Chem. Lett. 14, 4225-4229. doi: 10.1016/j.bmcl.2004.06.032.
24. Mieda, M., Williams, S. C., Richardson, J. A., Tanaka, K., and Yanagisawa, M. (2006). The dorsomedial hypothalamic nucleus as a putative food-entrainable circadian pacemaker. Proc. Natl. Acad. Sci. U.S.A. 103, 12150-12155. doi: 10.1073/pnas.0604189103.
25. Mikrouli, E., Wortwein, G., Soylu, R., Mathe, A. A., and Petersen, S. (2011). Increased numbers of orexin/hypocretin neurons in a genetic rat depression model. Neuropeptides 45, 401-406. doi: 10.1016/j.npep.2011.07.010.
26. Nollet, M., Gaillard, P., Minier, F., Tanti, A., Belzung, C., and Leman, S. (2011). Activation of orexin neurons in dorsomedial/perifornical hypothalamus and antidepressant reversal in a rodent model of depression. Neuropharmacology 61, 336-346. doi: 10.1016/j.neuropharm.2011.04.022.
27. Nollet, M., Gaillard, P., Tanti, A., Girault, V., Belzung, C., and Leman, S. (2012). Neurogenesis-independent antidepressant-like effects on behavior and stress axis response of a dual orexin receptor antagonist in a rodent model of depression. Neuropsychopharmacology 37, 2210-2221. doi: 10.1038/npp.2012.70.
28. Nollet, M., and Leman, S. (2013). Role of orexin in the pathophysiology of depression: potential for pharmacological intervention. CNS Drugs 27, 411-422. doi: 10.1007/s40263-013-0064-z.
29. O'Donnell, J. M., Marek, G. J., and Seiden, L. S. (2005). Antidepressant effects assessed using behavior maintained under a differential-reinforcement-of-low-rate (DRL) operant schedule. Neurosci. Biobehav. Rev. 29, 785-798. doi: 10.1016/j.neubiorev.2005.03.018.
30. O'Mahony, C. M., Sweeney, F. F., Daly, E., Dinan, T. G., and Cryan, J. F. (2010). Restraint stress-induced brain activation patterns in two strains of mice differing in their anxiety behaviour. Behav. Brain Res. 213, 148-154. doi: 10.1016/j.bbr.2010.04.038.
31. Ortega, J. E., Katner, J., Davis, R., Wade, M., Nisenbaum, L., Nomikos, G. G., et al. (2012). Modulation of neurotransmitter release in orexin/hypocretin-2 receptor knockout mice: a microdialysis study. J. Neurosci. Res. 90, 588-596. doi: 10.1002/jnr.22781.
32. Overstreet, D. H., and Wegener, G. (2013). The flinders sensitive line rat model of depression-25 years and still producing. Pharmacol. Rev. 65, 143-155. doi: 10.1124/pr.111.005397.
33. Radley, J. J., Arias, C. M., and Sawchenko, P. E. (2006). Regional differentiation of the medial prefrontal cortex in regulating adaptive responses to acute emotional stress. J. Neurosci. 26, 12967-12976. doi: 10.1523/JNEUROSCI.4297-06.2006.
34. Richards, J. K., Simms, J. A., Steensland, P., Taha, S. A., Borgland, S. L., Bonci, A., et al. (2008). Inhibition of orexin-1/hypocretin-1 receptors inhibits yohimbine-induced reinstatement of ethanol and sucrose seeking in Long-Evans rats. Psychopharmacology (Berl.) 199, 109-117. doi: 10.1007/s00213-008-1136-5.
35. Riemann, D. (2007). Insomnia and comorbid psychiatric disorders. Sleep Med. 8(Suppl. 4), S15-S20. doi: 10.1016/S1389-9457(08)70004-2.
36. Sakurai, T., Amemiya, A., Ishii, M., Matsuzaki, I., Chemelli, R. M., Tanaka, H., et al. (1998). Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 92, 573-585. doi: 10.1016/S0092-8674(00)80949-6.
37. Salomon, R. M., Ripley, B., Kennedy, J. S., Johnson, B., Schmidt, D., Zeitzer, J. M., et al. (2003). Diurnal variation of cerebrospinal fluid hypocretin-1 (Orexin-A) levels in control and depressed subjects. Biol. Psychiatry 54, 96-104. doi: 10.1016/S0006-3223(02)01740-7.
38. Scott, M. M., Marcus, J. N., Pettersen, A., Birnbaum, S. G., Mochizuki, T., Scammell, T. E., et al. (2011). Hcrtr1 and 2 signaling differentially regulates depression-like behaviors. Behav. Brain Res. 222, 289-294. doi: 10.1016/j.bbr.2011.02.044.
39. Sinton, C. M. (2011). Orexin/hypocretin plays a role in the response to physiological disequilibrium. Sleep Med. Rev. 15, 197-207. doi: 10.1016/j.smrv.2010.12.003.
40. Smart, D., Sabido-David, C., Brough, S. J., Jewitt, F., Johns, A., Porter, R. A., et al. (2001). SB-334867-A: the first selective orexin-1 receptor antagonist. Br. J. Pharmacol. 132, 1179-1182. doi: 10.1038/sj.bjp.0703953.
41. Spinazzi, R., Andreis, P. G., Rossi, G. P., and Nussdorfer, G. G. (2006). Orexins in the regulation of the hypothalamic-pituitary-adrenal axis. Pharmacol. Rev. 58, 46-57. doi: 10.1124/pr.58.1.4.
42. Taheri, S., Gardiner, J., Hafizi, S., Murphy, K., Dakin, C., Seal, L., et al. (2001). Orexin A immunoreactivity and preproorexin mRNA in the brain of Zucker and WKY rats. Neuroreport 12, 459-464. doi: 10.1097/00001756-200103050-00008.
43. Thase, M. E., Murck, H., and Post, A. (2010). Clinical relevance of disturbances of sleep and vigilance in major depressive disorder: a review. Prim. Care Companion J. Clin. Psychiatry 12. e1-e10. doi: 10.4088/PCC.08m00676gry.
44. Valenti, O., Lodge, D. J., and Grace, A. A. (2011). Aversive stimuli alter ventral tegmental area dopamine neuron activity via a common action in the ventral hippocampus. J. Neurosci. 31, 4280-4289. doi: 10.1523/JNEUROSCI.5310-10.2011.
45. Weller, T., Koberstein, R., Aissaoui, H., Clozel, M., and Fischli, W. (2005). "Substituted 1,2,3,4-tetrahydroisoquinoline derivatives," in International Patent # WO2005118548. Issued to Actelion Pharmaceuticals, Ltd. (Allschwil, CH).
46. Zamek-Gliszczynski, M. J., Ruterbories, K. J., Ajamie, R. T., Wickremsinhe, E. R., Pothuri, L., Rao, M. V., et al. (2011). Validation of 96-well equilibrium dialysis with non-radiolabeled drug for definitive measurement of protein binding and application to clinical development of highly-bound drugs. J. Pharm. Sci. 100, 2498-2507. doi: 10.1002/jps.22452.
47. Zhang, H. T., Whisler, L. R., Huang, Y., Xiang, Y., and O'Donnell, J. M. (2009). Postsyanptic a-2 adrenergic receptors are critical for the anti-depressant like effects of desipramine on behavior. Neuropsychopharmacology 34, 1067-1077. doi: 10.1038/npp.2008.184.